820 related articles for article (PubMed ID: 23827160)
21. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
Römermann K; Wanek T; Bankstahl M; Bankstahl JP; Fedrowitz M; Müller M; Löscher W; Kuntner C; Langer O
Nucl Med Biol; 2013 Oct; 40(7):873-8. PubMed ID: 23845421
[TBL] [Abstract][Full Text] [Related]
22. Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice.
Geyer J; Gavrilova O; Petzinger E
J Vet Pharmacol Ther; 2009 Feb; 32(1):87-96. PubMed ID: 19161460
[TBL] [Abstract][Full Text] [Related]
23. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar.
Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
Pharm Res; 2007 Sep; 24(9):1720-8. PubMed ID: 17380257
[TBL] [Abstract][Full Text] [Related]
24. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
Merino G; Jonker JW; Wagenaar E; Pulido MM; Molina AJ; Alvarez AI; Schinkel AH
Drug Metab Dispos; 2005 May; 33(5):614-8. PubMed ID: 15703302
[TBL] [Abstract][Full Text] [Related]
25. Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
Salphati L; Lee LB; Pang J; Plise EG; Zhang X
Drug Metab Dispos; 2010 Sep; 38(9):1422-6. PubMed ID: 20522663
[TBL] [Abstract][Full Text] [Related]
26. Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.
Marchetti S; Pluim D; van Eijndhoven M; van Tellingen O; Mazzanti R; Beijnen JH; Schellens JH
Invest New Drugs; 2013 Oct; 31(5):1125-35. PubMed ID: 23315030
[TBL] [Abstract][Full Text] [Related]
27. Impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of antiepileptic drugs in knockout mouse models.
Nakanishi H; Yonezawa A; Matsubara K; Yano I
Eur J Pharmacol; 2013 Jun; 710(1-3):20-8. PubMed ID: 23588114
[TBL] [Abstract][Full Text] [Related]
28. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
Agarwal S; Sane R; Ohlfest JR; Elmquist WF
J Pharmacol Exp Ther; 2011 Jan; 336(1):223-33. PubMed ID: 20952483
[TBL] [Abstract][Full Text] [Related]
29. ATP binding cassette transporters in two distinct compartments of the skin contribute to transdermal absorption of a typical substrate.
Hashimoto N; Nakamichi N; Uwafuji S; Yoshida K; Sugiura T; Tsuji A; Kato Y
J Control Release; 2013 Jan; 165(1):54-61. PubMed ID: 23089896
[TBL] [Abstract][Full Text] [Related]
30. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
Tang SC; de Vries N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2013 Sep; 346(3):486-94. PubMed ID: 23843632
[TBL] [Abstract][Full Text] [Related]
31. Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
Kort A; van Hoppe S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Mol Pharm; 2017 Oct; 14(10):3258-3268. PubMed ID: 28880088
[TBL] [Abstract][Full Text] [Related]
32. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
Poller B; Iusuf D; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2011 May; 39(5):729-35. PubMed ID: 21282407
[TBL] [Abstract][Full Text] [Related]
33. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
[TBL] [Abstract][Full Text] [Related]
34. Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening.
Tournier N; Valette H; Peyronneau MA; Saba W; Goutal S; Kuhnast B; Dollé F; Scherrmann JM; Cisternino S; Bottlaender M
J Nucl Med; 2011 Mar; 52(3):415-23. PubMed ID: 21321274
[TBL] [Abstract][Full Text] [Related]
35. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
Poller B; Wagenaar E; Tang SC; Schinkel AH
Mol Pharm; 2011 Apr; 8(2):571-82. PubMed ID: 21309545
[TBL] [Abstract][Full Text] [Related]
36. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
Pharmacol Res; 2018 Nov; 137():47-55. PubMed ID: 30253203
[TBL] [Abstract][Full Text] [Related]
37. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
Zhang S; Wang X; Sagawa K; Morris ME
Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
[TBL] [Abstract][Full Text] [Related]
38. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016).
Polli JW; Olson KL; Chism JP; John-Williams LS; Yeager RL; Woodard SM; Otto V; Castellino S; Demby VE
Drug Metab Dispos; 2009 Feb; 37(2):439-42. PubMed ID: 19056914
[TBL] [Abstract][Full Text] [Related]
39. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug.
Jonker JW; Wagenaar E; van Deemter L; Gottschlich R; Bender HM; Dasenbrock J; Schinkel AH
Br J Pharmacol; 1999 May; 127(1):43-50. PubMed ID: 10369454
[TBL] [Abstract][Full Text] [Related]
40. Induction of P-glycoprotein and Bcrp at the rat blood-brain barrier following a subchronic morphine treatment is mediated through NMDA/COX-2 activation.
Yousif S; Chaves C; Potin S; Margaill I; Scherrmann JM; Declèves X
J Neurochem; 2012 Nov; 123(4):491-503. PubMed ID: 22845665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
